Atomo Diagnostics

We are a global company. From our research, development and corporate office in Sydney, Australia; with production capabilities in the U.S.A. and manufacture and distribution in South Africa - we are Atomo.

On Monday, July 1, Atomo was privileged to attend the official launch event for the MyTest Vending Machine Program at the NSW Health Headquarters in Sydney.   With the increased push for HIV self-testing in Australia, as evidenced by the $44m commitment in the Federal Budget, the NSW Ministry of Health has been working exceptionally hard over the past several months to implement a vending machine program similar to that of the existing programs in South Australia and Queensland.    With a number of vending machines already established in key areas around the state and overwhelmingly positive feedback already coming in, Atomo is eager to watch as this program flourishes, providing necessary sexual health services to those who need them most – completely free of charge.   As always, we are incredibly proud to be contributing to the multi-faceted effort to virtually eliminate HIV in Australia with the supply of our HIV Self Test to the NSW MoH for this program.    For more information on this brand new initiative, please visit the link below:   https://lnkd.in/ga3RCcd3

🤝 New distribution agreement FebriDx® - Lumos’ rapid point-of-care test – is now available to health care practitioners in Australia and New Zealand, following the announcement of a new distribution agreement with Regional Health Care Group (RHCG), a Henry Schein company in Australia and New Zealand. FebriDx® is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx delivers results after 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings. Regional Health Care Group will sell the FebriDx test throughout Australia and New Zealand with sales and marketing activities commencing immediately. Lumos CEO, Doug Ward, said: “It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products. Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent U.S. launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.” Read the ASX release 👉 https://bit.ly/LDX-AU-NZ $LDX #LDX #Lumos #FebriDx #pointofcare #diagnostics #rapidtest #healthcare

Last Friday, June 14th, the Atomo team came together at Banish — an incredible space dedicated to helping Australians reduce their waste and ecological footprint. In an industry that presents numerous challenges, Atomo remains steadfast in its commitment to implementing best practices for sustainability. Our visit to Banish was a perfect reminder of the importance of this mission. Founded with the goal of equipping Australians with the right products and information to minimise waste, Banish offers practical tools and knowledge to empower individuals in making sustainable choices every day. Sustainable practices begin with the individual, and Friday's session with Lottie Dalziel was not only a way to reinforce the importance of minimising waste in a corporate environment, but a timely reminder to each of us as individuals that we can make a difference at home as well. We would like to encourage our followers to check Banish out and consider making a purchase from their fantastic range of sustainably crafted products. https://banish.com.au/

Atomo Diagnostics Limited (ASX: AT1) ASX Release | June 12, 2024 We’re thrilled to announce significant strides in public health with the expansion of our HIV Self-Testing initiatives across Australia. Here are the key highlights: Procurement and Revenue Growth: Atomo HIV Self-Tests will soon be procured through public health funding. Our participation in the national HIV Self-Test mail-out program is expected to generate approximately $1.3 million in revenue over the next two years. Expansion of Vending Machine Programs: National Rollout: Our vending machine pilot program, currently with 6 machines in South Australia, will expand to 70 machines nationwide by year-end. NSW Health Initiative: NSW Health has launched a separate pilot, “MyTest,” focusing on increasing access to free HIV self-tests through vending machines. This program aims to reach underserved populations, including those facing barriers to regular health testing. National HIV Self-Test Mail-Out Program: Led by the National Association of People with HIV Australia (NAPWHA), this initiative aims to improve testing rates among at-risk groups by providing free HIV self-tests via mail. With significant promotion through platforms like Grindr, we are witnessing increased awareness and demand. John Kelly, CEO of Atomo, stated, "The government’s investment in HIV Self-Testing marks a pivotal moment in public health. Following the success of rapid testing during the COVID-19 pandemic, we’re seeing a shift towards more decentralised healthcare delivery. Self-testing is now recognised globally as a cost-effective method for early detection and improved health outcomes." Atomo is proud to supply the only HIV Self-Test listed on the Australian Register of Therapeutic Goods (ARTG). Our commitment to innovation continues as we support these transformative public health initiatives. Read the full ASX Release at the link below. https://lnkd.in/gsAE24t5 #AtomoDiagnostics #PublicHealth #HIVTesting #Innovation #Healthcare

ICYMI: Atomo CEO John Kelly presented at the Coffee Microcaps online webinar yesterday, Thursday June 30. To view John's presentation, please click the link below and skip to 31:30 https://lnkd.in/gDhRgZqR

This coming Thursday, May 30, Coffee Microcaps will be hosting a virtual morning meeting in which Atomo Diagnostics CEO, John Kelly, will be presenting. John will be presenting at 9:30am, discussing the positive news in the Federal Budget surrounding HIV self-testing, what that means for Atomo's domestic HIV Self Test business and the future direction of Atomo's OEM business. To register to attend the event, please click the link below. https://bit.ly/3R1TSHV

What a fantastic initiative from our partners at Newfoundland Diagnostics for European Testing Week 2024. With the effectiveness of antiretroviral medication in treating HIV, breaking down barriers to testing is the most practical way we can work towards ending HIV across the world. Congratulations to all involved on creating such an impactful installation! Read more: https://lnkd.in/gZQSwcX2

Atomo Diagnostics welcomes the Australian Federal government’s commitment to fund expansion of HIV Self-Testing in the Budget. As part of the A$43.9m package, people with or at risk of HIV will receive unprecedented support through better prevention, testing, workforce training and information, with the Government committed to eliminating HIV transmission by 2030. Additionally, more people in at-risk groups will get free HIV self-test kits through the expanded national HIV self-test mail-out program as well as wider access to HIV testing by extending the South Australia-based HIV testing vending machine pilot to every state and territory.  Atomo CEO John Kelly said: “We are delighted to see the government recognise the critical need to ensure HIV Self-Test availability across the community and fund the rapid expansion of the national HIV self-test mail-out program and the HIV self-test vending machine pilots. Both have proven extremely successful in increasing testing rates among groups not currently testing via healthcare facility-based services.” You can read the full ASX release at the link below: https://lnkd.in/e7J9MZVp

ICYMI: Atomo Diagnostics CEO John Kelly gave a presentation of Atomo's FY24 Q3 results this morning, Tuesday April 30. To watch the webinar, click the link below. https://lnkd.in/gYnNqS74